Finoriq research workspace
Aprea Therapeutics, Inc. (APRE) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Aprea Therapeutics, Inc. (APRE).
Company Snapshot
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
- Company
- Aprea Therapeutics, Inc. (APRE)
- Ticker
- APRE
- Market Cap
- $8.4M
- Latest Price
- $0.677
- Industry
- Biotech & Pharma
Aprea Therapeutics, Inc. (APRE) Recent Insider Transactions
Recent market insider transaction records indexed for Aprea Therapeutics, Inc. (APRE).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| Gilad OrenPresident/CEO | P | Acquired | $25,009 | 2026-01-30 |
| Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr | P | Acquired | $5,073 | 2026-01-30 |
| Duey MarcCommon Stock | P | Acquired | $25,000 | 2025-12-10 |
| Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr | P | Acquired | $5,825 | 2025-12-10 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.